A case report of a patient with BRAF V600E-mutated advanced NSCLC treated with dabrafenib monotherapy who progressed after an initial response to BRAF inhibition reported a newly acquired KRAS G12D mutation [76]. Here, BRAF is linked to non-small cell lung carcinoma.